



Ad hoc release

STADA: Dr. Axel Müller resigns his Executive Board mandate

Bad Vilbel, August 7, 2013 – Dr. rer. nat. Axel Müller, Chief Production and Development Officer, has announced his resignation from the Executive Board of STADA Arzneimittel AG with effect from August 7, 2013 at 12:00 am. Following the nearly complete operational implementation of the Group-wide cost-efficiency program "STADA - build the future", which has been ongoing since 2010, this step is being taken for personal reasons since Dr. Müller wants to devote himself to other tasks in the future. The resignation has been made on the most agreeable terms with the Supervisory Board, which released Dr. Müller from his responsibilities until the regular expiration of his Executive Board contract on December 31, 2014. The Supervisory Board and Executive Board wish to express their tremendous gratitude and recognition to Dr. Müller for his many years of very successful work on STADA's Executive Board and management.

The Supervisory Board has decided today not to fill the Executive Board position of Production and Development for the time being. Executive Board responsibilities for the area of Production and Development will in future be carried out as follows: Mr. Retzlaff, Chairman of the Executive Board, takes on additional responsibility for the areas Production, Research and Development as well as Purchasing and Procurement. Mr. Kraft will in future assume additional responsibility for the area Biotechnology and Dr. Wiedenfels takes over the area Quality Assurance and Quality Control.

Additional information:

STADA Arzneimittel AG / Corporate Communications / Stadastraße 2–18 / 61118 Bad Vilbel – Germany / Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-506 / E-mail:

communications@stada.de

Or visit us in the Internet at www.stada.com.

Executive Board: Hartmut Retzlaff (Chairman) / Helmut Kraft / Dr. Axel Müller / Dr. Matthias Wiedenfels
Chairman of the Supervisory Board: Dr. Martin Abend